This company is no longer active
Magenta Therapeutics Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Magenta Therapeutics.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 21.1% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | None |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Magenta Therapeutics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
6/30/2023 | N/A | -69 | -70 | -73 | N/A |
3/31/2023 | N/A | -83 | -83 | -83 | N/A |
12/31/2022 | N/A | -76 | -67 | -67 | N/A |
9/30/2022 | N/A | -76 | -66 | -66 | N/A |
6/30/2022 | N/A | -77 | -68 | -66 | N/A |
3/31/2022 | N/A | -77 | -64 | -62 | N/A |
12/31/2021 | N/A | -71 | -61 | -60 | N/A |
9/30/2021 | N/A | -70 | -59 | -58 | N/A |
6/30/2021 | N/A | -70 | -58 | -58 | N/A |
3/31/2021 | N/A | -72 | -64 | -64 | N/A |
12/31/2020 | N/A | -75 | -64 | -64 | N/A |
9/30/2020 | N/A | -80 | -66 | -66 | N/A |
6/30/2020 | N/A | -83 | -64 | -63 | N/A |
3/31/2020 | N/A | -82 | -61 | -59 | N/A |
12/31/2019 | N/A | -77 | -60 | -57 | N/A |
9/30/2019 | N/A | -70 | -61 | -54 | N/A |
6/30/2019 | N/A | -65 | -62 | -53 | N/A |
3/31/2019 | N/A | -61 | -56 | -47 | N/A |
12/31/2018 | N/A | -58 | -50 | -42 | N/A |
9/30/2018 | N/A | -49 | -41 | -37 | N/A |
6/30/2018 | N/A | -40 | -34 | -32 | N/A |
3/31/2018 | N/A | -42 | -30 | -28 | N/A |
12/31/2017 | N/A | -36 | -24 | -22 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if MGTA's forecast earnings growth is above the savings rate (2.2%).
Beneficios vs. Mercado: Insufficient data to determine if MGTA's earnings are forecast to grow faster than the US market
Beneficios de alto crecimiento: Insufficient data to determine if MGTA's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if MGTA's revenue is forecast to grow faster than the US market.
Ingresos de alto crecimiento: Insufficient data to determine if MGTA's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if MGTA's Return on Equity is forecast to be high in 3 years time